Pokhrel Akriti, Olayemi Adeniran, Ogbonda Stephanie, Nair Kiron, Wang Jen Chin
Department of Internal Medicine, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
Department of Epidemiology, West Virginia University, Morgantown, West Virginia, USA.
Eur J Haematol. 2023 May;110(5):554-563. doi: 10.1111/ejh.13936. Epub 2023 Feb 12.
Sickle cell disease mainly affects African Americans, and studies on racial differences in sickle cell disease outcomes are scanty. This study examined racial and ethnic differences in sickle cell disease prevalence, comorbidities, and outcomes.
Using the National Inpatient Sample database from 2016 to 2018, we identified patients' records with a diagnosis of sickle cell disease using the International Classification of Diseases, Tenth Revision codes. The overall study population was further stratified by race into Blacks, Whites, and Hispanics. Using logistic regression, comorbidities and outcomes among sickle cell disease patients were compared between the three races/ethnicities.
Of the 74 817 hospitalized for sickle cell disease, 69 889 (93.4%) were Blacks, 3603 (4.8%) were Hispanics, and 1325 (1.8%) were Whites. Compared to Whites, Blacks were more likely to have significantly higher odds of sickle cell crisis (odds ratio [OR]: 3.32; 95% confidence interval [CI]: 2.66-4.14) and blood transfusion (OR: 1.66; 95% CI: 1.37-2.02). There was no difference in mortality between Blacks and Whites. Compared to Hispanics, Blacks had significantly higher odds of sickle cell crisis (OR: 1.35; 95% CI: 1.19-1.53) and blindness (OR: 2.94; 95% CI: 1.22-7.11), lower odds of asplenia (OR: 0.57; 95% CI: 0.45-0.71) and gallstones (OR: 0.75; 95% CI: 0.58-0.95). However, Blacks had statistically significantly lower odds of mortality of 0.60 (95% CI: 0.38-0.93) than Hispanics.
Prevalent sickle cell type, severity, complications, and comorbidities vary in different races. Physicians need to be aware of these differences to manage sickle cell patients efficiently. This study hopes to inform further research regarding the reasons for varying disease characteristics among racial groups and bridge a gap in tailored management protocols.
镰状细胞病主要影响非裔美国人,而关于镰状细胞病结局种族差异的研究较少。本研究调查了镰状细胞病在患病率、合并症及结局方面的种族和民族差异。
利用2016年至2018年的全国住院患者样本数据库,我们使用国际疾病分类第十版编码确定了诊断为镰状细胞病的患者记录。总体研究人群按种族进一步分为黑人、白人和西班牙裔。使用逻辑回归比较了三个种族/民族中镰状细胞病患者的合并症及结局。
在74817名因镰状细胞病住院的患者中,69889名(93.4%)为黑人,3603名(4.8%)为西班牙裔,1325名(1.8%)为白人。与白人相比,黑人发生镰状细胞危象(比值比[OR]:3.32;95%置信区间[CI]:2.66 - 4.14)和输血(OR:1.66;95% CI:1.37 - 2.02)的几率显著更高。黑人和白人的死亡率无差异。与西班牙裔相比,黑人发生镰状细胞危象(OR:1.35;95% CI:1.19 - 1.53)和失明(OR:2.94;95% CI:1.22 - 7.11)的几率显著更高,而无脾(OR:0.57;95% CI:0.45 - 0.71)和胆结石(OR:0.75;95% CI:0.58 - 0.95)的几率更低。然而,黑人的死亡率比西班牙裔在统计学上显著低0.60(95% CI:0.38 - 0.93)。
不同种族中镰状细胞病的流行类型、严重程度、并发症及合并症各不相同。医生需要了解这些差异以便有效地管理镰状细胞病患者。本研究希望为进一步研究种族群体间疾病特征差异的原因提供信息,并弥合定制管理方案方面的差距。